Anticipation and treatment of male infertility
Presentation
Kallistem is a biotech company specialized in spermatogenesis. The company was founded in 2012 with the objective to anticipate and treat male infertility. It promotes a technology and expertise developed by Philippe Durand and Marie-Helene Perrard, two internationally renowned scientists in the field of the reproductive biology and more specially in in vitro spermatogenesis.
Kallistem has developed, in collaboration with its partners, two original and innovating technologies of germinal cell culture for male fertility preservation and the treatment of male infertility.
|
Technology name |
Definition |
Description |
Application |
|
«Artificial testicle » |
Cellular therapy technology which allows germinal stem cells to ‘mature’ and produce, ex vivo, fertilising spermatozoa. |
Medically Assisted Procreation (preservation and treatment) |
|
|
In vitro testicular toxicity model |
Cell culture system which models, in vitro, the impact of a chemical substance on 80% of human and animal spermatogenesis (production of round spermatids). |
In vitro testicular toxicology |
Keopz.fr